Home » The News » Page 51

Category Archives: The News

Quick info on new developments

Fighting P. aeruginosa (Part I)

Posted on by — No Comments ↓

It has never been easy to cure Pseudomonas aeruginosa infections.  Few antibiotics nowadays have reliable activity against this problem pathogen that seems to have more built-in resistance features than most other Gram-negatives.  In the past, cephalosporins, aztreonam, penems, ciprofloxacin, and aminoglycosides were useful drugs with reliably cidal activity, especially when Continue reading Fighting P. aeruginosa (Part I)→

Snapshot: HCV Drugs in Development

Posted on by — No Comments ↓

It’s becoming a daunting task to follow the field given the rapid-fire release of study results and the many recent submissions of new direct-acting antiviral (DAA) drugs. All will be given as cocktails, with or without interferon or ribavirin, and for various durations depending on genotype (GT) and other factors.  How Continue reading Snapshot: HCV Drugs in Development→

Here They Are: Dalbavancin and Oritavancin – The New Long-Acting Lipoglycopeptides

Posted on by — No Comments ↓

The development history of glycopeptide drugs is anything but normal.  Daptomycin (Cubicin®) was abandoned by Lilly but resurrected by Francis Tally at Cubist by adjusting the dosing schedule to once daily and careful uptitration.  The drug did superbly in a landmark endocarditis trial and everything looked rosy.  Then we learned Continue reading Here They Are: Dalbavancin and Oritavancin – The New Long-Acting Lipoglycopeptides→